Take the Money and Run in This Biotech

by Sam Collins | May 1, 2013 1:33 am

Gilead Sciences (NASDAQ:GILD[1]) — On Nov. 19, with the stock trading near $37.50, the Trade of the Day[2] recommended it, saying, “This large-cap biotech is well positioned to gain market share.”

The stock gapped up to a new high following positive results from a study for its Hepatitis C treatment. However, Gilead suffered two setbacks this week when the FDA declined to approve two of its HIV drugs.

With GILD up 35% from our initial buy point, the FDA rejections coupled with the Collins-Bollinger Reversal (CBR) sell signal last week and an MACD sell signal, tell us that it’s time to cash in the profits on GILD.

However, this high-quality biotech is not a short-sale recommendation. In fact, if the stock were to pull back to support below $43, it would again be a candidate for our buy list.

05 01 13 gild 300x199 Take the Money and Run in This Biotech
Click to Enlarge

chart key 300x84 Take the Money and Run in This Biotech[3]

  1. GILD: http://studio-5.financialcontent.com/investplace/quote?Symbol=GILD
  2. Trade of the Day: http://investorplace.com/2012/11/trade-of-the-day-gilead-sciences-nasdaq-gild/
  3. [Image]: http://investorplace.com/wp-content/uploads/2011/04/chart-key.gif

Source URL: http://investorplace.com/2013/05/trade-of-the-day-gilead-sciences-nasdaq-gild-3/
Short URL: http://invstplc.com/1nGClk4